Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

 

2019 ASH Review on Combinations or Sequences of Targeted Agents in CLL: Ibrutinib + Venetoclax for the 1st-Line Treatment - Should MRD Status at EOT Be Driving Treatment Decisions?

April 14, 2020

0 Comments
Login to view comments. Click here to Login
Leukemia